ThirtyFiveBio

ThirtyFiveBio is an early-stage drug discovery company founded in 2021 by a team of experienced pharmaceutical industry professionals and biotechnology entrepreneurs. The company is dedicated to developing first-in-class small molecule inhibitors of G protein-coupled receptor 35 (GPR35) for the treatment of gastrointestinal (GI) diseases. ThirtyFiveBio leverages its fully functional drug discovery platform to identify multiple unique series of first-in-class small molecule GPR35 inhibitors and advances their development through lead optimization efforts.